Lipella Pharmaceuticals (LIPO) Competitors $0.63 0.00 (0.00%) As of 08/15/2025 11:05 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. GOVX, PHIO, HOOK, PHXM, IBIO, SNSE, IMCC, BFRI, BCDA, and APREShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include GeoVax Labs (GOVX), Phio Pharmaceuticals (PHIO), HOOKIPA Pharma (HOOK), PHAXIAM Therapeutics (PHXM), iBio (IBIO), Sensei Biotherapeutics (SNSE), IM Cannabis (IMCC), Biofrontera (BFRI), BioCardia (BCDA), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors GeoVax Labs Phio Pharmaceuticals HOOKIPA Pharma PHAXIAM Therapeutics iBio Sensei Biotherapeutics IM Cannabis Biofrontera BioCardia Aprea Therapeutics Lipella Pharmaceuticals (NASDAQ:LIPO) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Does the media refer more to LIPO or GOVX? In the previous week, GeoVax Labs had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Lipella Pharmaceuticals. GeoVax Labs' average media sentiment score of 0.43 beat Lipella Pharmaceuticals' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Neutral GeoVax Labs Neutral Which has more volatility and risk, LIPO or GOVX? Lipella Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500. Is LIPO or GOVX more profitable? GeoVax Labs has a net margin of -403.88% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% GeoVax Labs -403.88%-408.80%-279.89% Do analysts prefer LIPO or GOVX? GeoVax Labs has a consensus target price of $8.88, indicating a potential upside of 1,068.69%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in LIPO or GOVX? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, LIPO or GOVX? Lipella Pharmaceuticals has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K5.25-$5.02M-$4.08-0.15GeoVax Labs$3.95M3.06-$24.99M-$2.01-0.38 SummaryGeoVax Labs beats Lipella Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.81M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-0.1520.7630.8025.13Price / Sales5.25364.18466.77115.19Price / CashN/A42.3037.4059.05Price / Book0.408.659.096.18Net Income-$5.02M-$54.65M$3.26B$265.11M7 Day Performance11.50%6.56%7.31%4.20%1 Month Performance-13.70%7.53%5.43%1.99%1 Year Performance-80.31%13.69%30.59%23.75% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella PharmaceuticalsN/A$0.63flatN/A-81.2%$2.81M$536.36K-0.154GOVXGeoVax Labs1.8494 of 5 stars$0.72-7.3%$8.88+1,133.7%-77.3%$11.46M$3.95M-0.3610Short Interest ↑PHIOPhio Pharmaceuticals2.5748 of 5 stars$2.35-1.1%$14.00+497.0%-15.5%$11.26MN/A-0.3710News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownHOOKHOOKIPA Pharma3.4703 of 5 stars$0.92-0.7%$4.50+390.7%-83.0%$11.18M$43.95M-0.16160Short Interest ↓PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049IBIOiBio1.1947 of 5 stars$0.64+0.6%$5.00+684.9%-59.9%$10.54M$375K0.00100SNSESensei Biotherapeutics4.6059 of 5 stars$8.21-5.1%$55.00+569.9%-28.7%$10.35MN/A-0.3640News CoverageGap DownIMCCIM Cannabis0.949 of 5 stars$2.49-5.3%N/A-12.5%$10.09M$54.47M-3.90340News CoverageEarnings ReportAnalyst DowngradeShort Interest ↓BFRIBiofrontera2.6816 of 5 stars$0.99-2.0%$2.75+179.2%-19.8%$9.99M$38.00M-0.4470News CoverageEarnings ReportGap UpBCDABioCardia3.685 of 5 stars$1.81-7.7%$25.00+1,281.2%-33.8%$9.96M$60K-0.7840Earnings ReportShort Interest ↓APREAprea Therapeutics3.5917 of 5 stars$1.77+4.1%$15.50+775.7%-50.4%$9.90M$1.50M-0.767Earnings ReportAnalyst RevisionGap DownHigh Trading Volume Related Companies and Tools Related Companies GOVX Competitors PHIO Competitors HOOK Competitors PHXM Competitors IBIO Competitors SNSE Competitors IMCC Competitors BFRI Competitors BCDA Competitors APRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access